Salivary LINC00657 as a Diagnostic Biomarker for Oral Squamous Cell Carcinoma
1 other identifier
observational
36
1 country
1
Brief Summary
This study was designed to verify the role of salivary LINC00657 as a diagnostic marker in oral squamous cell carcinoma (OSCC) patients as compared to oral lichen planus (OLP) (as an example of oral potentially malignant lesions) and normal individuals, and to show its relation to miR-106a. A total of 36 participants were included.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
February 25, 2023
CompletedFirst Submitted
Initial submission to the registry
March 26, 2023
CompletedFirst Posted
Study publicly available on registry
April 20, 2023
CompletedApril 20, 2023
April 1, 2023
1 year
March 26, 2023
April 19, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
LINC00657 level in salivary samples from all participants measured using PCR
quantitative real-time PCR is used to detect LINC00657 levels in saliva samples from patients with OSCC and OPMD compared to healthy subjects
level of miR-106a is measured after the completion of all salivary sample collection carried at the 1 day of enrollment of subjects in the investigation after diagnosis confirmation
Secondary Outcomes (1)
miR-106a level in salivary samples from the included subjects evaluated by PCR
level of miR-106a is measured after the completion of all salivary sample collection carried at the 1 day of enrollment of subjects in the investigation
Study Arms (3)
Group I
12 patients diagnosed with OSCC.
Group II
12 patients diagnosed with OLP.
Group III
12 systemically free individuals with no oral mucosal lesions.
Eligibility Criteria
\- patients recruited from the outpatient clinic of departments of oral diagnosis and medicine and periodontology Fayoum, Beni-Suef and Ahram-Candian universities
You may qualify if:
- group I : oral squamous cell carcinoma lesions (OSCC)
- group II: oral lichen planus lesions (OLP)
- group III: systemically healthy volunteers
You may not qualify if:
- oral lesions other than OSCC / OLP in group I and II
- any oral lesion in group III
- pregnant females
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
faculty of dentistry, Fayoum university
Al Fayyum, Egypt
Related Publications (1)
Tarrad NAF, Hassan S, Shaker OG, AbdelKawy M. "Salivary LINC00657 and miRNA-106a as diagnostic biomarkers for oral squamous cell carcinoma, an observational diagnostic study". BMC Oral Health. 2023 Dec 12;23(1):994. doi: 10.1186/s12903-023-03726-0.
PMID: 38087258DERIVED
Biospecimen
saliva
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nayroz Tarrad, as. professor
faculty of dentistry, Fayoum university
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- associate professor
Study Record Dates
First Submitted
March 26, 2023
First Posted
April 20, 2023
Study Start
January 1, 2022
Primary Completion
January 1, 2023
Study Completion
February 25, 2023
Last Updated
April 20, 2023
Record last verified: 2023-04
Data Sharing
- IPD Sharing
- Will not share